• Positive opinion is based on comprehensive data confirming that Sandoz biosimilar pegfilgrastim matches the reference medicine in terms of safety, efficacy and quality
• Sandoz seeks approval in the same indication as the reference medicine, to reduce the duration of neutropenia and the incidence of febrile neutropenia due to chemotherapy, some of the most serious side effects of cancer chemotherapy[1]
• Sandoz is the global leader in biosimilars and continues to improve patient access and support sustainable healthcare with seven …

• Novartis to focus Sandoz division in US on higher growth areas and will sell selected portions of the Sandoz US portfolio to Aurobindo Pharma USA Inc.
   
• Agreement comprises the Sandoz US generic oral solids and Sandoz US dermatology businesses with approximately 300 products and H1 2018 sales of USD 0.6 billion
   
• Transaction supports the Sandoz strategy of focusing on complex generics, value-added medicines and biosimilars to achieve sustainable and profitable growth in the US

Basel, September 6, 2018 – Novartis …

• Biosimilar Hyrimoz^® (adalimumab) approved for use in all same indications as reference medicine*** including rheumatology, gastroenterology and dermatology
• Early therapeutic intervention is essential in rheumatoid arthritis, supporting urgency of treatments like Hyrimoz
• Fourth Sandoz biosimilar approved in Europe** in past 18 months, and seventh in total, underscoring Sandoz commitment to making access happen through a robust portfolio

Holzkirchen, July 27, 2018 – Sandoz, a Novartis division …

• Net sales grew 5% (cc[1], +7% USD) mainly driven by:
  • Cosentyx grew to USD 701 million, (+40% cc) with strong growth in all indications in the US and EU
  • Entresto sales more than doubled to USD 239 million, (+113% cc) driven by continued uptake worldwide
  • Oncology grew 10% (cc) driven by continued growth from Promacta/Revolade, Tafinlar + Mekinist and Jakavi, uptake of Kisqali and Kymriah and contribution from the AAA acquisition
• Core[ …

• Zessly^® (infliximab) matched the reference medicine in terms of safety and efficacy at 54 weeks, even in patients who switched from the reference medicine to Zessly[1]
• Switching from the reference medicine to Erelzi^® (etanercept) did not impact efficacy and safety in patients with moderate to severe rheumatoid arthritis at 48 weeks[2]
• Nearly 320 million people in Europe are expected to have limited access to disease-modifying anti-rheumatic medicines, underscoring the value of Zessly and Erelzi[3 …